Plain-English translation of NCT06057519 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a higher daily dose of rifampicin—a common tuberculosis medication—works better and remains safe compared to the standard dose that doctors typically prescribe. Some patients will receive 1,800 mg daily, while others receive the usual dose based on their body weight. The research team will carefully monitor both groups for side effects, how well the medication works, and how the body processes the medication.
Tuberculosis is a serious infection that requires strong medications to cure. Doctors want to know if giving a higher, standard dose of this medication could help patients recover faster and more reliably, without causing more harm to the liver or other organs.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the higher dose (1,800 mg daily) or the standard dose of rifampicin. You'll take your medication regularly and visit the study clinic for check-ups where doctors will draw blood tests to monitor your liver health, check how you're responding to treatment, and watch for any side effects. The study tracks how quickly your TB improves and compares the two groups to see which dose is safer and works best.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Italy
Netherlands